A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Minoxidil

Arteriolar Vasodilator class · 3 generic manufacturers · 6 ANDAs filed at FDA.

First FDA approval1988-11-14
Generic availableYes · 3 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$14.7M in CY2024 Part D spend996K claims · 361K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.095/unit
13 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.136
Across all dosage forms in distribution.
Highest NADAC
$0.171
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Minoxidil used for?

Minoxidil is a Arteriolar Vasodilator medication tracked in Medicare Part D.

Is there a generic for Minoxidil?

Yes. 6 ANDAs filed at FDA, 3 generic manufacturers currently shipping.

How much does my plan pay for Minoxidil?

Across 329 Part D plans, Minoxidil averages $0.136/unit (NADAC). Lowest available: $0.095/unit. Highest in distribution: $0.171/unit.

Is Minoxidil on the FDA shortage list?

No. Minoxidil is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Arteriolar Vasodilator1 alternative in D1
01
Hydralazine
Brand: Hydralazine
$0.027Lowest NADAC
17Generic mfrs
$119.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (13 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.